Contents:
Limitations in DCE-MRI specific to prostate cancer include motion artifact, specifically from rectal and colonic peristalsis. Further, hyperintense findings on MRI may correlate not only with abnormal tumor tissue but any changes in vascularity including BPH nodules, post-biopsy changes, and prostatitis. At present, an additional limitation of DCE-MRI of the prostate, which also applies to the imaging of all other organ systems, is the lack of standardization of sequences and analysis parameters[ 5 ].
With the availability of a wide range of imaging sequences on most MR units, a defining objective of many studies today is to identify the role of DCE-MRI as part of a multi-parametric examination[ 50 ]. We have reviewed DCE-MRI acquisition and data analysis methods for the detection and monitoring of cancer in the prostate. Potential clinical applications of DCE-MRI for prostate cancer include detection, localization and staging, assessment of tumor aggressiveness, and assessment of treatment response. Limitations include lack of standardized acquisition and analysis methods which can results in variability in the results.
We expect that with the standardization of these methods will encourage more wide spread use of DCE-MRI in prostate cancer imaging. Advanced Search. This Article. Academic Rules and Norms of This Article. Citation of this article. Dynamic contrast-enhanced magnetic resonance imaging of prostate cancer: A review of current methods and applications. Corresponding Author of This Article. Publishing Process of This Article. Research Domain of This Article. Radiology, Nuclear Medicine and Medical Imaging. Article-Type of This Article.
Open-Access Policy of This Article. This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. Number of Hits and Downloads for This Article. Total Article Views All Articles published online. Times Cited of This Article. Journal Information of This Article.
Published by Baishideng Publishing Group Inc. All rights reserved. World J Radiol. Conflict-of-interest statement : This manuscript is not published anywhere else; all authors conform that there is no conflict of interests including none for related to commercial, personal, political, intellectual, or religious interests. Open-Access : This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers.
Relationship between MR signal and contrast agent concentration. Choice of arterial input function. Shown is the model-based arterial input function, based on the Parker function. A: Transverse T2-weighted image. The curves are characteristic of the types of time-intensity curves obtained with dynamic contrast-enhanced MRI. The green ROI shows moderately slow and slight enhancement wash-in pattern.
This is characteristic for many benign, enhancing tissues, such as normal prostate tissue. The red ROI shows a rapid rise in signal intensity with subsequent wash-out as is typical in tumors.
Parametric maps for the semi-quantitative parameters, including; B: Peak-enhancement; C: Enhancement slope; D: Wash-out slope; E: Time-to-peak; and F: Intensity curve or contrast medium concentration at 60 s. Parametric maps for the semi-quantitative parameters, including B: Peak-enhancement; C: Enhancement slope; D: Wash-out slope; E: Time-to-peak; and F: Intensity curve or contrast medium concentration at 60 s. Assessment of prostate cancer aggressiveness.
External-beam radiation therapy. High-intensity focused ultrasound. Dynamic contrast-enhanced MRI studies in oncology with an emphasis on quantification, validation and human studies. Clin Radiol. Dynamic contrast-enhanced magnetic resonance imaging in oncology.
Top Magn Reson Imaging. Estimating kinetic parameters from dynamic contrast-enhanced T 1 -weighted MRI of a diffusable tracer: standardized quantities and symbols. J Magn Reson Imaging. Classic models for dynamic contrast-enhanced MRI. NMR Biomed. Overview of dynamic contrast-enhanced MRI in prostate cancer diagnosis and management. Clin Pharmacol Ther. Magn Reson Med.
Tofts PS. Regional blood flow, capillary permeability, and compartmental volumes: measurement with dynamic CT--initial experience.
1. Curr Med Imaging Rev. May 1;3(2) Dynamic contrast enhanced MRI (DCE-MRI) enables the quantitative assessment of tumor status and has found application in both pre-clinical tumor models as well as clinical oncology. Dynamic contrast-enhanced magnetic resonance imaging in oncology. (1) National Institutes of Health, Clinical Center, Diagnostic Radiology Department.
Comparison between population average and experimentally measured arterial input function in predicting biopsy results in prostate cancer. Acad Radiol. Magn Reson Imaging. Practical considerations in T1 mapping of prostate for dynamic contrast enhancement pharmacokinetic analyses.
Prostate cancer localization with dynamic contrast-enhanced MR imaging and proton MR spectroscopic imaging. Prostate cancer: local staging at 3-T endorectal MR imaging--early experience. Localization of prostate cancer using 3T MRI: comparison of T2-weighted and dynamic contrast-enhanced imaging. J Comput Assist Tomogr. Dynamic contrast enhanced, pelvic phased array magnetic resonance imaging of localized prostate cancer for predicting tumor volume: correlation with radical prostatectomy findings.
J Urol. Dynamic contrast-enhanced MRI of prostate cancer at 3 T: a study of pharmacokinetic parameters. Create an account Institutional Access:. The alert successfully saved. The alert did not successfully save. Please try again later. Arlinghaus, Richard G. Abramson M.
Immunohistochemical subtypes predict survival in metastatic breast cancer receiving high-dose chemotherapy with autologous haematopoietic stem cell transplantation. Use of mpMRI in active surveillance for localized prostate cancer. Predictive power of the ESUR scoring system for prostate cancer diagnosis verified with targeted MR-guided in-bore biopsy. Most of the data in the literature suggest that ADCs are lower in malignant lymph nodes. Dynamic contrast-enhanced MR perfusion imaging of head and neck tumors at 3 Tesla. Finally, we constructed the Rad-scores using linear combination of the selected features and non-linear method of could offer better performance. Information from the National Library of Medicine Choosing to participate in a study is an important personal decision.
Barnes, Jeffrey D. Blume, Sarah Avery M. Yankeelov, Anna G. Sorace, "Dynamic contrast-enhanced magnetic resonance imaging and diffusion-weighted magnetic resonance imaging for predicting the response of locally advanced breast cancer to neoadjuvant therapy: a meta-analysis," J. Citation Only. RIS Zotero. Save this study. Warning You have reached the maximum number of saved studies Listing a study does not mean it has been evaluated by the U. Federal Government. Read our disclaimer for details. Results First Posted : June 8, Last Update Posted : June 8, Study Description.
It is an agent that prevents angiogenesis, which is new blood vessel formation. The use of pazopanib described in this study is a standard of care, but the additional MRI and blood tests that will be performed are experimental. FDA Resources. Arms and Interventions.